Marhttps://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.17-0305%20%20
Conclusion
These studies are the first to demonstrate the equivalence of iMSC and adMSC for treatment of IBD, in a widely used rodent DSS colitis model. In all aspects evaluated, iMSC were equally potent in terms of suppressing intestinal inflammation and stimulating intestinal healing. These studies also revealed a significant stimulatory effect of iMSC cellular therapy on epithelial proliferation and angiogenesis, and restoration of normal microbiome populations.
- Forums
- ASX - By Stock
- IPSC - MSC for bowel disease
CYP
cynata therapeutics limited
Add to My Watchlist
7.69%
!
1.2¢
Marhttps://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10....
-
Top Stories
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
